- Home
- KNSA vs ACHC Comparison
KNSA vs ACHC Comparison
Compare KNSA & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- ACHC
- Stock Information
- Founded
- KNSA 2015
- ACHC 2005
- Country
- KNSA United Kingdom
- ACHC United States
- Employees
- KNSA N/A
- ACHC N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- ACHC Medical Specialities
- Sector
- KNSA Health Care
- ACHC Health Care
- Exchange
- KNSA Nasdaq
- ACHC Nasdaq
- Market Cap
- KNSA 1.9B
- ACHC 1.7B
- IPO Year
- KNSA 2018
- ACHC N/A
- Fundamental
- Price
- KNSA $35.71
- ACHC $23.72
- Analyst Decision
- KNSA Strong Buy
- ACHC Strong Buy
- Analyst Count
- KNSA 6
- ACHC 10
- Target Price
- KNSA $40.83
- ACHC $42.85
- AVG Volume (30 Days)
- KNSA 439.9K
- ACHC 2.4M
- Earning Date
- KNSA 10-28-2025
- ACHC 10-29-2025
- Dividend Yield
- KNSA N/A
- ACHC N/A
- EPS Growth
- KNSA N/A
- ACHC N/A
- EPS
- KNSA 0.07
- ACHC 1.52
- Revenue
- KNSA $529,332,000.00
- ACHC $3,229,609,000.00
- Revenue This Year
- KNSA $37.21
- ACHC $7.48
- Revenue Next Year
- KNSA $11.99
- ACHC $7.40
- P/E Ratio
- KNSA $539.78
- ACHC $15.58
- Revenue Growth
- KNSA 56.18
- ACHC 5.64
- 52 Week Low
- KNSA $17.82
- ACHC $17.13
- 52 Week High
- KNSA $35.82
- ACHC $79.83
- Technical
- Relative Strength Index (RSI)
- KNSA 72.49
- ACHC 63.11
- Support Level
- KNSA $33.25
- ACHC $22.88
- Resistance Level
- KNSA $34.16
- ACHC $22.35
- Average True Range (ATR)
- KNSA 0.83
- ACHC 0.79
- MACD
- KNSA 0.07
- ACHC 0.30
- Stochastic Oscillator
- KNSA 95.59
- ACHC 79.17
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.